Immunome IMNM
NASDAQ IMNM
$18.07 +0.15 (+0.81%)
As of: Oct 21, 2026 · 2:37 PM EDT

Immunome (IMNM) Short term Debt (2020 - 2021)

Updated

Immunome's Short term Debt was $366,000 in Q1 2021, unchanged from the prior quarter.

Analysis

Immunome (IMNM) Short term Debt (2020 - 2021) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,136.90 Bn 1,105.48 Bn 19.71 Bn
2 Johnson & Johnson 617.06 Bn 535.59 Bn 17.26 Bn
3 AbbVie 501.38 Bn 474.49 Bn 12.70 Bn
4 Merck 367.41 Bn 321.79 Bn 12.21 Bn
5 Novartis Ag 297.92 Bn 261.91 Bn 11.24 Bn
6 Astrazeneca 261.31 Bn 235.00 Bn 12.86 Bn
7 Amgen 236.29 Bn 191.69 Bn 7.24 Bn
8 Gilead Sciences 190.40 Bn 164.60 Bn 6.22 Bn
9 Pfizer 169.55 Bn 116.19 Bn 10.94 Bn
10 Immunome 2.05 Bn 17.45 Mn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2021 366,000.00
Dec 31, 2020 366,000.00
Sep 30, 2020 305,000.00
API Access

Immunome Short term Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=short-term-debt&ticker=IMNM&period=max&api_key=YOUR_API_KEY